Q-omics provides the consensus-scored METTL21A profile across patient tissues and cancer cell-line models. METTL21A expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, METTL21A is differentially expressed in 14, with the highest sampling consensus in LUAD. Additionally, METTL21A RNA expression shows 20,037 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LIHC, LUAD, and ACC as cancer lineages where METTL21A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for METTL21A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes METTL21A survival associations across molecular data types. METTL21A RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible METTL21A RNA expression–survival associations across cancer types. High METTL21A expression shows unfavorable associations in LIHC, ACC, KIRP, LGG and UVM, but favorable associations in UCS. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for METTL21A RNA expression.
This table summarizes METTL21A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in LUAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for METTL21A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. METTL21A shows lower tumor expression in KICH and THCA and higher tumor expression in LUAD, HNSC, STAD and LIHC. The LUAD box plot shows higher METTL21A RNA expression in tumor versus normal tissue (log2 FC = +1.096, t-test p < 0.001).
This table shows molecular features associated with METTL21A in patient tissues and cancer cell lines. In patient samples, METTL21A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, METTL21A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Lymphoma.
